Literature DB >> 8227726

Pharmacokinetics of vancomycin during continuous hemodiafiltration.

C Santré1, O Leroy, M Simon, H Georges, B Guery, C Beuscart, G Beaucaire.   

Abstract

OBJECTIVE: To study the pharmacokinetics of vancomycin in three patients with acute renal failure related to multi-organ failure during continuous venovenous hemodiafiltration (CVVHD).
DESIGN: Prospective exploratory, open-labelled study.
SETTING: Critical Care Unit in a University Medical Centre. PATIENTS: 3 patients exhibiting hemodynamic instability and oligo-anuric acute renal failure requiring extra-renal epuration were included in this study. INTERVENTION: Every patient received 7.5 mg/kg IV vancomycin over 1 h for a documented or suspected nosocomial staphylococcal infection. Serum and dialysate outlets samples were collected before infusion and 1, 3, 6, 12, 18, 24 after the end of infusion. MEASUREMENTS AND
RESULTS: Mean age was 58.7 years (range 41-79) and mean SAPS 15.7 (9-23). The mean peak concentrations were 27.3 mg/l (range 15.6-45.6) one hour after the end of infusion. The average remaining vancomycin concentration 24 h after the onset of infusion was 3.6 mg/l (range 2.6-4.5). The mean terminal disposition rate constant and elimination half-life were 0.05 h-1 and 13.9 h respectively. Mean total body clearance was 38.9 +/- 4.3 ml/min and dialysate outlet (DO) clearance 4.2 +/- 1.3 ml/min. The mean volume of distribution was 47.4 +/- 6.4 l.
CONCLUSION: CVVHD is effective for vancomycin elimination. In these patients, the elimination half-life is almost constant, involving a following injection of vancomycin 12 h later to achieve effective concentrations.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8227726     DOI: 10.1007/bf01694710

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  7 in total

1.  Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection.

Authors:  W E Peetermans; J J Hoogeterp; A M Hazekamp-van Dokkum; P van den Broek; H Mattie
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

2.  Elimination of vancomycin during hemofiltration.

Authors:  P Rawer; K E Seim
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-06       Impact factor: 3.267

3.  Removal of therapeutic drugs by continuous arteriovenous hemofiltration.

Authors:  T A Golper; J Pulliam; W M Bennett
Journal:  Arch Intern Med       Date:  1985-09

Review 4.  Vancomycin revisited.

Authors:  F V Cook; W E Farrar
Journal:  Ann Intern Med       Date:  1978-06       Impact factor: 25.391

5.  Continuous arteriovenous hemofiltration. A report of six months' experience.

Authors:  A A Kaplan; R E Longnecker; V W Folkert
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

6.  Continuous arteriovenous hemofiltration in the critically ill patient. Clinical use and operational characteristics.

Authors:  A Lauer; A Saccaggi; C Ronco; M Belledonne; S Glabman; J P Bosch
Journal:  Ann Intern Med       Date:  1983-10       Impact factor: 25.391

7.  Disposition of vancomycin during hemofiltration.

Authors:  G R Matzke; M B O'Connell; A J Collins; P R Keshaviah
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

  7 in total
  10 in total

1.  Presence and accuracy of drug dosage recommendations for continuous renal replacement therapy in tertiary drug information references.

Authors:  Sean K Gorman; Richard S Slavik; Stefanie Lam
Journal:  Can J Hosp Pharm       Date:  2012-05

2.  Predicting the dose of vancomycin in ICU patients receiving different types of RRT therapy: a model-based meta-analytic approach.

Authors:  Guillaume Claisse; Paul J Zufferey; Jane C Trone; Nicolas Maillard; Xavier Delavenne; Silvy Laporte; Edouard Ollier
Journal:  Br J Clin Pharmacol       Date:  2019-04-07       Impact factor: 4.335

3.  Initial vancomycin dosing recommendations for critically ill patients undergoing continuous venovenous hemodialysis.

Authors:  Lyndsay M van de Vijsel; Sandra A N Walker; Scott E Walker; Sharon Yamashita; Andrew Simor; Michelle Hladunewich
Journal:  Can J Hosp Pharm       Date:  2010-05

4.  Dosing Recommendations for Continuous Venovenous Hemodiafiltration with AN69 Filter Membranes and Prismaflex Dialyzers.

Authors:  Eugenia Yeh; Glen Brown
Journal:  Can J Hosp Pharm       Date:  2009-11

5.  A Robust Statistical Approach to Analyse Population Pharmacokinetic Data in Critically Ill Patients Receiving Renal Replacement Therapy.

Authors:  Sanjoy Ketan Paul; Jason A Roberts; Jeffrey Lipman; Renae Deans; Mayukh Samanta
Journal:  Clin Pharmacokinet       Date:  2019-02       Impact factor: 6.447

Review 6.  Pharmacokinetics of drugs used in critically ill adults.

Authors:  B M Power; A M Forbes; P V van Heerden; K F Ilett
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

7.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 8.  Clinical pharmacokinetics during continuous haemofiltration.

Authors:  F Bressolle; J M Kinowski; J E de la Coussaye; N Wynn; J J Eledjam; M Galtier
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

9.  A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics.

Authors:  Darren M Roberts; Xin Liu; Jason A Roberts; Priya Nair; Louise Cole; Michael S Roberts; Jeffrey Lipman; Rinaldo Bellomo
Journal:  Crit Care       Date:  2015-03-13       Impact factor: 9.097

10.  Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation.

Authors:  Susan J Lewis; Bruce A Mueller
Journal:  SAGE Open Med       Date:  2018-05-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.